Cargando…

PRMT5 inhibitors on the (myeloma) road

Detalles Bibliográficos
Autores principales:	Gulla, Annamaria, Hideshima, Teru, Anderson, Kenneth C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291180/ https://www.ncbi.nlm.nih.gov/pubmed/30613345 http://dx.doi.org/10.18632/oncotarget.26392

Ejemplares similares

Protein Arginine Methyltransferase 5 (PRMT5) has prognostic relevance and is a druggable target in Multiple Myeloma
por: Gullà, Annamaria, et al.
Publicado: (2017)

Signaling Pathway Mediating Myeloma Cell Growth and Survival
por: Hideshima, Teru, et al.
Publicado: (2021)

The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2018)

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
por: Hideshima, Teru, et al.
Publicado: (2008)

Multiple myeloma: the (r)evolution of current therapy and a glance into the future
por: Gulla', Annamaria, et al.
Publicado: (2020)

IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells
por: HIDESHIMA, HIROMASA, et al.
Publicado: (2014)

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010)

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities
por: Yamamoto, Leona, et al.
Publicado: (2021)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010)

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma
por: Johnstone, Megan, et al.
Publicado: (2022)

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications
por: Harada, Takeshi, et al.
Publicado: (2017)

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival
por: Ohguchi, Hiroto, et al.
Publicado: (2017)

Prmt5 differentiates developmental vs regenerative myogenesis
por: Zhang, Ting, et al.
Publicado: (2015)

PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
por: Xia, Tian, et al.
Publicado: (2021)

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma
por: Jakubikova, Jana, et al.
Publicado: (2023)

The Road to a Cure: Emerging Treatments for Multiple Myeloma
por: Caers, Jo
Publicado: (2020)

Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
por: Milan, Enrico, et al.
Publicado: (2023)

Correction: PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
por: Xia, Tian, et al.
Publicado: (2021)

PRMT1 loss sensitizes cells to PRMT5 inhibition
por: Gao, Guozhen, et al.
Publicado: (2019)

TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma
por: Nakayama, Kazuhide, et al.
Publicado: (2018)

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma
por: Bae, Jooeun, et al.
Publicado: (2021)

Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)

Development of Macrocyclic PRMT5–Adaptor Protein Interaction Inhibitors
por: Krzyzanowski, Adrian, et al.
Publicado: (2022)

Autophagy dictates sensitivity to PRMT5 inhibitor in breast cancer
por: Brobbey, Charles, et al.
Publicado: (2023)

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Retraction: Fatty acid synthase is a novel therapeutic target in multiple myeloma
por: Okawa, Yutaka, et al.
Publicado: (2008)

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2017)

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma
por: Adamia, Sophia, et al.
Publicado: (2022)

Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs
por: Cirstea, Diana, et al.
Publicado: (2013)

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer
por: Hideshima, Teru, et al.
Publicado: (2021)

Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer
por: Liu, Shuangjie, et al.
Publicado: (2022)

Protein arginine methyltransferases PRMT1, PRMT4/CARM1 and PRMT5 have distinct functions in control of osteoblast differentiation
por: Dashti, Parisa, et al.
Publicado: (2023)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

The Protective Function of PRMT1 in Alcohol‐Induced Hepatocellular Carcinoma
por: Jeong, Jong‐Min, et al.
Publicado: (2020)

A Novel Role for CCL3 (MIP-1α) in Myeloma-induced Bone Disease via Osteocalcin Downregulation and Inhibition of Osteoblast Function
por: Vallet, Sonia, et al.
Publicado: (2011)

The Methyltransferases PRMT4/CARM1 and PRMT5 Control Differentially Myogenesis in Zebrafish
por: Batut, Julie, et al.
Publicado: (2011)

Discovery of Potent and Selective Covalent Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors
por: Lin, Hong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cnoam0bebu4jkdol4qp26o4m8n